Pharmacology, Toxicology and Pharmaceutical Science
Artesunate
100%
Antimalarial Agent
82%
Amodiaquine
75%
Parkinson's Disease
71%
Infection
71%
Prevalence
70%
Adverse Event
61%
Combination Therapy
55%
Schistosomiasis
54%
Clinical Trial
53%
Plasmodium falciparum
46%
Praziquantel
45%
Disease
41%
Chagas Disease
40%
Randomized Controlled Trial
40%
Malaria Falciparum
40%
Monotherapy
35%
Ivermectin
34%
Pharmacokinetics
34%
Artemisinin
33%
Amodiaquine Plus Artesunate
33%
Visceral Leishmaniasis
31%
Dihydroartemisinin
30%
Elimination
29%
Placebo
26%
Observational Study
26%
Ethanol
24%
Mixed Model
23%
HIV
23%
Tablet
21%
Benznidazole
21%
Mefloquine
21%
Albendazole
21%
Helminth
21%
Miltefosine
20%
Parasitemia
20%
Carotid Atherosclerosis
19%
Arteriosclerosis
19%
Fexinidazole
19%
Onchocerca volvulus
19%
Microfilaria (Nematode Larva)
19%
Acute Heart Infarction
19%
Moxidectin
19%
Amphotericin B
19%
Chemotherapy
18%
Schistosoma
17%
Biological Marker
16%
Tolerability
15%
Intestine Volvulus
14%
Obesity
14%
Medicine and Dentistry
Parkinson's Disease
91%
Infection
74%
Prevalence
64%
Clinical Trial
57%
COVID-19
54%
Disease
51%
Chagas Disease
42%
Systematic Review
39%
Arteriosclerosis
39%
Congestive Heart Failure
39%
Meta-Analysis
38%
Ivermectin
34%
Randomized Controlled Trial
33%
Human Immunodeficiency Virus
33%
Cohort Effect
31%
Observational Study
31%
Red Wine
29%
Lifestyle Modification
29%
Physical Activity
28%
Cohort Analysis
27%
Exercise
27%
Placebo
26%
Schistosomiasis
26%
Onchocerciasis
24%
Comorbidity
24%
Adverse Event
23%
Single Drug Dose
23%
Helminth
23%
Moxidectin
23%
Benznidazole
21%
Visceral Leishmaniasis
21%
Albendazole
21%
Fexinidazole
20%
Onchocerca volvulus
20%
Gut Microbiome
19%
Mild Cognitive Impairment
19%
Cardiovascular System
19%
Neglected Tropical Diseases
19%
Severe Acute Respiratory Syndrome Coronavirus 2
19%
Metabolic Syndrome
19%
Quality of Life
19%
Public Health
19%
Diagnosis
18%
Population
18%
Degenerative Disease
18%
Cognitive Defect
17%
Patient-Data
16%
Arm
15%
Migraine
15%
Early Diagnosis
14%